HIF2a inhibitors for the treatment of VHL disease

Oncotarget. 2015 Sep 15;6(27):23036-7. doi: 10.18632/oncotarget.4564.
No abstract available

Keywords: HIF2a inhibitors; VHL; hypoxia; renal cancer.

Publication types

  • Editorial
  • Review

MeSH terms

  • Animals
  • Basic Helix-Loop-Helix Transcription Factors / antagonists & inhibitors*
  • Disease Models, Animal
  • Humans
  • Hypoxia
  • Kidney Diseases / drug therapy*
  • Kidney Diseases / genetics*
  • Oxygen / chemistry
  • RNA, Messenger / metabolism
  • Transforming Growth Factor beta / metabolism
  • Vascular Endothelial Growth Factor A / metabolism
  • Von Hippel-Lindau Tumor Suppressor Protein / genetics*
  • Zebrafish

Substances

  • Basic Helix-Loop-Helix Transcription Factors
  • RNA, Messenger
  • Transforming Growth Factor beta
  • Vascular Endothelial Growth Factor A
  • endothelial PAS domain-containing protein 1
  • Von Hippel-Lindau Tumor Suppressor Protein
  • VHL protein, human
  • Oxygen